...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and diagnostic laboratory immunology >Enzyme-Linked Immunoassay Using Recombinant trans-Sialidase of Trypanosoma cruzi Can Be Employed for Monitoring of Patients with Chagas' Disease after Drug Treatment
【24h】

Enzyme-Linked Immunoassay Using Recombinant trans-Sialidase of Trypanosoma cruzi Can Be Employed for Monitoring of Patients with Chagas' Disease after Drug Treatment

机译：可使用克氏锥虫的重组反式唾液酸酶的酶联免疫分析法对药物治疗后南美锥虫病患者进行监测

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

trans-Sialidase is an enzyme present on the surface of Trypanosoma cruzi and is an important antigen recognized by sera from patients with Chagas' disease. In the present study we investigated whether the benznidazole treatment of patients with Chagas' disease induced changes in the reactivity of serum toward a recombinant form of trans-sialidase in order to develop an assay for monitoring of patients after treatment for Chagas' disease, which is needed at Chagas' disease control centers. By using an enzyme-linked immunosorbent assay containing a recombinant protein corresponding to the catalytic domain of trans-sialidase, we found that the antigen had a high specificity for sera from untreated patients with Chagas' disease. Sera from healthy individuals or patients with active visceral leishmaniasis minimally cross-reacted with the antigen. Anti-trans-sialidase immunoglobulin was detected in 98% of 151 untreated patients with Chagas' disease. Of these, 124 patients were treated for 60 days with benznidazole (5 mg/kg of body weight/day), and their sera were assayed for reactivity with the recombinant trans-sialidase. By using this methodology, three groups of patients could be established. The first group (60 patients), which was considered to have been successfully treated, showed no reactivity after treatment. The second group (46 patients) still showed signs of infection, and after treatment their sera recognized trans-sialidase, but with reduced titers. The third group (18 patients) was considered to be resistant to drug treatment, and their sera presented identical reactivities before and after treatment. These results suggest that determination of the absence of antibodies to recombinant trans-sialidase in treated patients by the present assay is indicative of treatment success, while the presence of antibodies may indicate the persistence of infection. Therefore, this method may be useful for the diagnosis and monitoring of patients undergoing benznidazole treatment.
机译： trans -唾液酸酶是克鲁姆氏锥虫表面上存在的一种酶，是查加斯病患者血清中识别的重要抗原。在本研究中，我们调查了苯甲硝唑治疗查加斯病患者是否诱导血清对重组形式的反式唾液酸酶的反应性变化，以开发一种监测治疗后患者的方法恰加斯病控制中心需要的恰加斯病。通过使用包含与 trans-唾液酸酶催化域相对应的重组蛋白的酶联免疫吸附法，我们发现该抗原对未经治疗的恰加斯氏病患者的血清具有高度特异性。健康个体或活动性内脏利什曼病患者的血清与抗原的交叉反应最少。在151例未经治疗的恰加斯病患者中，有98％检测到抗 trans 唾液酸酶免疫球蛋白。其中124例患者接受苯硝唑（5 mg / kg体重/天）治疗60天，并测定其血清与重组 trans-唾液酸酶的反应性。通过使用这种方法，可以建立三组患者。被认为已成功治疗的第一组（60例患者）在治疗后无反应。第二组（46名患者）仍然显示出感染的迹象，在治疗后，他们的血清识别出反式-唾液酸酶，但滴度降低。第三组（18例患者）被认为对药物治疗有抵抗力，他们的血清在治疗前后呈现相同的反应性。这些结果表明，通过本试验确定在治疗的患者中不存在针对重组反式-唾液酸酶的抗体，这表明治疗成功，而抗体的存在可能表明感染持续存在。因此，该方法可能对诊断和监测接受苯硝唑治疗的患者有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号